Patents by Inventor Joshua Rabinowitz
Joshua Rabinowitz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11607510Abstract: The present invention an electronic inhaler for the delivery of pharmaceuticals through vaporization.Type: GrantFiled: October 12, 2021Date of Patent: March 21, 2023Assignee: THE TRUSTEES OF PRINCETON UNIVERSITYInventor: Joshua Rabinowitz
-
Publication number: 20220071292Abstract: The present disclosure generally relates to compositions, and related devices and methods, useful in vaporizing devices such as electronic cigarettes. The composition may comprise nicotine, at least one solvent, and at least one ion pairing agent, and may be vaporized to form a condensation aerosol, wherein inhalation of the aerosol allows for deposition of nicotine with the respiratory system, including deep lung deposition. The vaporizing device may comprise a vaporization unit, a battery, and an integrated circuit coupled to the battery, wherein the integrated circuit is configured to control the battery for rapid initial vaporization without overheating, producing thermal degradation products, or draining battery energy. The battery may operate with pulse width modulation for at least a portion of the time the vaporizing device is being used.Type: ApplicationFiled: November 12, 2021Publication date: March 10, 2022Inventors: Joshua RABINOWITZ, Mark SCATTERDAY
-
Publication number: 20220023551Abstract: The present invention an electronic inhaler for the delivery of pharmaceuticals through vaporization.Type: ApplicationFiled: October 12, 2021Publication date: January 27, 2022Inventor: Joshua Rabinowitz
-
Patent number: 11202470Abstract: The present disclosure generally relates to compositions, and related devices and methods, useful in vaporizing devices such as electronic cigarettes. The composition may comprise nicotine, at least one solvent, and at least one ion pairing agent, and may be vaporized to form a condensation aerosol, wherein inhalation of the aerosol allows for deposition of nicotine with the respiratory system, including deep lung deposition. The vaporizing device may comprise a vaporization unit, a battery, and an integrated circuit coupled to the battery, wherein the integrated circuit is configured to control the battery for rapid initial vaporization without overheating, producing thermal degradation products, or draining battery energy. The battery may operate with pulse width modulation for at least a portion of the time the vaporizing device is being used.Type: GrantFiled: May 21, 2014Date of Patent: December 21, 2021Assignee: NJOY, Inc.Inventors: Joshua Rabinowitz, Mark Scatterday
-
Patent number: 11154667Abstract: The present invention an electronic inhaler for the delivery of pharmaceuticals through vaporization.Type: GrantFiled: April 27, 2017Date of Patent: October 26, 2021Assignee: THE TRUSTEES OF PRINCETON UNIVERSITYInventor: Joshua Rabinowitz
-
Patent number: 10772862Abstract: Methods and compositions for treating Ras-related cancers are provided that involve targeting lipid scavenging. Methods and compositions for identifying and/or characterizing more or less responsive cancers are also provided.Type: GrantFiled: October 15, 2018Date of Patent: September 15, 2020Assignees: The Trustees of Princeton University, Memorial Sloan Kettering Cancer CenterInventors: Joshua Rabinowitz, Jurre Kamphorst, Craig Thompson, Justin Cross
-
Publication number: 20190134324Abstract: The present invention an electronic inhaler for the delivery of pharmaceuticals through vaporization.Type: ApplicationFiled: April 27, 2017Publication date: May 9, 2019Applicant: THE TRUSTEES OF PRINCETON UNIVERSITYInventor: Joshua RABINOWITZ
-
Publication number: 20190046489Abstract: Methods and compositions for treating Ras-related cancers are provided that involve targeting lipid scavenging. Methods and compositions for identifying and/or characterizing more or less responsive cancers are also provided.Type: ApplicationFiled: October 15, 2018Publication date: February 14, 2019Inventors: Joshua Rabinowitz, Jurre Kamphorst, Craig Thompson, Justin Cross
-
Patent number: 10130600Abstract: Methods and compositions for treating Ras-related cancers are provided that involve targeting lipid scavenging. Methods and compositions for identifying and/or characterizing more or less responsive cancers are also provided.Type: GrantFiled: May 9, 2014Date of Patent: November 20, 2018Assignees: Memorial Sloan Kettering Cancer Center, The Trustees of Princeton UniversityInventors: Joshua Rabinowitz, Jurre Kamphorst, Craig Thompson, Justin Cross
-
Patent number: 9757407Abstract: Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. The antiviral activity of enzyme inhibitors is demonstrated.Type: GrantFiled: December 21, 2015Date of Patent: September 12, 2017Assignee: The Trustees of Princeton UniversityInventors: Josh Munger, Bryson Bennett, Thomas Shenk, Joshua Rabinowitz
-
Publication number: 20160346309Abstract: Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. The antiviral activity of enzyme inhibitors is demonstrated.Type: ApplicationFiled: December 21, 2015Publication date: December 1, 2016Inventors: Josh Munger, Bryson Bennett, Thomas Shenk, Joshua Rabinowitz
-
Publication number: 20160120832Abstract: Methods and compositions for treating Ras-related cancers are provided that involve targeting lipid scavenging. Methods and compositions for identifying and/or characterizing more or less responsive cancers are also provided.Type: ApplicationFiled: May 9, 2014Publication date: May 5, 2016Applicants: Memorial Sloan Kettering Cancer Center, The Trustees of Princeton UniveristyInventors: Joshua Rabinowitz, Jurre Kamphorst, Craig Thompson, Justin Cross
-
Publication number: 20150250800Abstract: Methods of treating headache with antipsychotics are provided. A kit for treating headache is also provided, comprising an antipsychotic and a device for rapid delivery of the antipsychotic.Type: ApplicationFiled: May 26, 2015Publication date: September 10, 2015Inventors: Ron L. Hale, Peter M. Lloyd, Amy T. Lu, Patrik Munzar, Joshua Rabinowitz, Roman Skowronski
-
Publication number: 20150139949Abstract: The present invention provides methods and compounds for treating viral infections using combinations modulators of an HCV-associated component and modulators of host cell enzymes. The present invention also provides methods and compounds for treating viral infections using combinations of modulators of host cell enzymes and other agents that work, at least in part by modulating hos factors.Type: ApplicationFiled: May 19, 2014Publication date: May 21, 2015Inventors: Emre KOYUNCU, Thomas E. SHENK, Joshua RABINOWITZ
-
Patent number: 9029413Abstract: Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, and in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. Antiviral activity of enzyme inhibitors is demonstrated.Type: GrantFiled: April 3, 2012Date of Patent: May 12, 2015Assignee: The Trustees of Princeton UniversityInventors: Josh Munger, Bryson Bennett, Thomas Shenk, Joshua Rabinowitz
-
Publication number: 20140345635Abstract: The present disclosure generally relates to compositions, and related devices and methods, useful in vaporizing devices such as electronic cigarettes. The composition may comprise nicotine, at least one solvent, and at least one ion pairing agent, and may be vaporized to form a condensation aerosol, wherein inhalation of the aerosol allows for deposition of nicotine with the respiratory system, including deep lung deposition. The vaporizing device may comprise a vaporization unit, a battery, and an integrated circuit coupled to the battery, wherein the integrated circuit is configured to control the battery for rapid initial vaporization without overheating, producing thermal degradation products, or draining battery energy. The battery may operate with pulse width modulation for at least a portion of the time the vaporizing device is being used.Type: ApplicationFiled: May 21, 2014Publication date: November 27, 2014Applicant: NJOY, Inc.Inventors: Joshua RABINOWITZ, Mark SCATTERDAY
-
Publication number: 20130065850Abstract: Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. The antiviral activity of enzyme inhibitors is demonstrated.Type: ApplicationFiled: April 3, 2012Publication date: March 14, 2013Applicant: THE TRUSTEES OF PRINCETON UNIVERSITYInventors: Josh MUNGER, Bryson BENNETT, Thomas SHENK, Joshua RABINOWITZ
-
Patent number: 8158677Abstract: Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. The antiviral activity of enzyme inhibitors is demonstrated.Type: GrantFiled: June 2, 2008Date of Patent: April 17, 2012Assignee: The Trustees of Princeton UniversityInventors: Josh Munger, Bryson Bennett, Thomas Shenk, Joshua Rabinowitz
-
Publication number: 20090239830Abstract: Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. The antiviral activity of enzyme inhibitors is demonstrated.Type: ApplicationFiled: June 2, 2008Publication date: September 24, 2009Inventors: Josh Munger, Bryson Bennett, Thomas Shenk, Joshua Rabinowitz
-
Publication number: 20080038363Abstract: A device, method, and system for producing a condensation aerosol are disclosed. The device includes a chamber having an upstream opening and a downstream opening which allow gas to flow through the chamber, and a heat-conductive substrate located at a position between the upstream and downstream openings. Formed on the substrate is a drug composition film containing a therapeutically effective dose of a drug when the drug is administered in aerosol form. A heat source in the device is operable to supply heat to the substrate to produce a substrate temperature greater than 300 oC, and to substantially volatilize the drug composition film from the substrate in a period of 2 seconds or less. The device produces an aerosol containing less than about 10% by weight drug composition degradation products and at least 50% of the drug composition of said film.Type: ApplicationFiled: March 16, 2007Publication date: February 14, 2008Inventors: Alejandro Zaffaroni, Joshua Rabinowitz